AR087468A1 - Metodo para tratar la esquizofrenia - Google Patents

Metodo para tratar la esquizofrenia

Info

Publication number
AR087468A1
AR087468A1 ARP120102867A ARP120102867A AR087468A1 AR 087468 A1 AR087468 A1 AR 087468A1 AR P120102867 A ARP120102867 A AR P120102867A AR P120102867 A ARP120102867 A AR P120102867A AR 087468 A1 AR087468 A1 AR 087468A1
Authority
AR
Argentina
Prior art keywords
hydroxy
oxy
halogen
aliphatic hydrocarbon
group
Prior art date
Application number
ARP120102867A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR087468A1 publication Critical patent/AR087468A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Uso de un derivado de ácido graso representado por la fórmula (1) en donde L, M y N son hidrógeno, hidroxi, halógeno, alquilo inferior, hidroxialquilo (inferior), alcanoil inferior-oxi u oxo, en donde el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH3 o -CH2OH, -COCH2OH, -COOH o uno de sus derivados funcionales; B es un enlace simple, -CH2-CH2-, -CH=CH-, -CºC-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -CºC-CH2- o -CH2-CºC-; Z es un resto seleccionado del grupo de fórmulas (2) o enlace simple, en donde R4 y R5 son hidrógeno, hidroxi, halógeno, alquilo inferior, alcoxi inferior o hidroxialquilo (inferior), en donde R4 y R5 no son hidroxi y alcoxi inferior al mismo tiempo; Z1 y Z2 son oxígeno, nitrógeno o azufre; R6 y R7 son alquilo inferior opcionalmente sustituido, que esta opcionalmente ligado para formar alquileno inferior; R1 es un residuo hidrocarbonado alifático inferior o medio bivalente saturado o insaturado, que no está sustituido o que esta sustituido con halógeno, alquilo inferior, hidroxi, oxo, arilo o grupo heterocíclico y al menos uno de átomo de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxigeno, nitrógeno o azufre; y Ra es un residuo hidrocarbonado alifático inferior o medio saturado o insaturado, que no está sustituido o que está sustituido con halógeno, oxo, hidroxi, alquilo inferior, alcoxi inferior, alcanoil inferior-oxi, cicloalquilo (inferior), cicloalquiloxi (inferior), arilo, ariloxi, grupo heterociclico o grupo heterocíclico-oxi; alcoxi inferior; alcanoil inferior-oxi; cicloalquilo (inferior); cicloalquiloxi (inferior); arilo; ariloxi; grupo heterocíclico; grupo heterocíclico-oxi y al menos uno de átomo de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxigeno, nitrógeno o azufre; para la preparación de un medicamento para tratar esquizofrenia en un sujeto mamífero que lo necesita.Reivindicación 6: Uso de acuerdo con la reivindicación 1, en donde el derivado de ácido graso es ácido (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]heptanoico, (Z)-7-[(1R,2R,3R,5S)-3,5-dihidroxi-2-(3-oxodecil)ciclopentil]hept-5-enoato de (+)-isopropilo o ácido (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctil)-5-oxocicloperitil)hept 2 enoico.
ARP120102867A 2011-08-05 2012-08-06 Metodo para tratar la esquizofrenia AR087468A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161515418P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
AR087468A1 true AR087468A1 (es) 2014-03-26

Family

ID=47627335

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102867A AR087468A1 (es) 2011-08-05 2012-08-06 Metodo para tratar la esquizofrenia

Country Status (18)

Country Link
US (2) US8592483B2 (es)
EP (1) EP2739278A4 (es)
JP (2) JP6193230B2 (es)
KR (1) KR20140076551A (es)
CN (2) CN107903173A (es)
AR (1) AR087468A1 (es)
AU (2) AU2012293157A1 (es)
BR (1) BR112014002712A8 (es)
CA (1) CA2842455A1 (es)
HK (1) HK1252353A1 (es)
IL (2) IL230552A (es)
MX (1) MX359697B (es)
NZ (1) NZ620300A (es)
RU (1) RU2648474C2 (es)
SG (1) SG10201606442QA (es)
TW (2) TWI619497B (es)
WO (1) WO2013022079A1 (es)
ZA (1) ZA201400707B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103450128B (zh) * 2013-08-15 2015-04-08 河南中帅医药科技股份有限公司 用于治疗青光眼的前列腺素类似物中间体Corey醛的制备方法
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
ES2972595T3 (es) 2019-04-24 2024-06-13 Yamaha Motor Co Ltd Vehículo de montar a horcajadas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW224942B (es) 1990-04-04 1994-06-11 Adka Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
ITRM20010356A1 (it) * 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
TWI384988B (zh) * 2005-01-27 2013-02-11 Sucampo Ag 處理中樞神經系統失常用之組成物
EP2329825B1 (en) * 2005-03-04 2015-10-07 Sucampo AG Method and composition for treating peripheral vascular diseases
US7211703B2 (en) * 2005-04-27 2007-05-01 Calgon Carbon Corporation Method of separating E and Z isomers of an alkene alcohol and derivatives thereof
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
AU2008276840B2 (en) * 2007-07-19 2013-10-03 R-Tech Ueno, Ltd. Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound
US9259409B2 (en) * 2011-01-24 2016-02-16 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Also Published As

Publication number Publication date
EP2739278A1 (en) 2014-06-11
IL254289A0 (en) 2017-10-31
RU2648474C2 (ru) 2018-03-26
JP6193230B2 (ja) 2017-09-06
CN103841966A (zh) 2014-06-04
BR112014002712A8 (pt) 2017-06-20
AU2017203092A1 (en) 2017-06-01
HK1252353A1 (zh) 2019-05-24
KR20140076551A (ko) 2014-06-20
IL230552A0 (en) 2014-03-31
CA2842455A1 (en) 2013-02-14
US20130035393A1 (en) 2013-02-07
US8592483B2 (en) 2013-11-26
MX359697B (es) 2018-10-08
BR112014002712A2 (pt) 2017-06-13
ZA201400707B (en) 2014-11-26
RU2014108423A (ru) 2015-09-10
TWI619497B (zh) 2018-04-01
AU2012293157A1 (en) 2014-03-13
EP2739278A4 (en) 2015-03-18
TW201808302A (zh) 2018-03-16
SG10201606442QA (en) 2016-09-29
WO2013022079A1 (en) 2013-02-14
TWI619498B (zh) 2018-04-01
IL230552A (en) 2017-09-28
JP2014527048A (ja) 2014-10-09
AU2017203092B2 (en) 2018-11-08
TW201316992A (zh) 2013-05-01
JP2017222708A (ja) 2017-12-21
MX2014001409A (es) 2014-05-28
US20140031428A1 (en) 2014-01-30
CN107903173A (zh) 2018-04-13
NZ620300A (en) 2015-09-25

Similar Documents

Publication Publication Date Title
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
AR073158A1 (es) Metodo y composicion para modular el crecimiento de celulas madre
PE20181519A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
AR106472A1 (es) Inhibidores de acc y usos de los mismos
AR098048A1 (es) Inhibidores de fgfr4
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
PE20190801A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR087591A1 (es) Derivados de ciclohexil azetidina como inhibidores de jak
UY33731A (es) ?derivados de ácido amino-fenil-pentanoico sustituidos como inhibidores de nep?
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
AR097543A1 (es) COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
ECSP10010167A (es) Composiciones oftálmicas novedosas
PE20142366A1 (es) Compuestos triazolo como inhibidores de pde 10
AR087468A1 (es) Metodo para tratar la esquizofrenia
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.

Legal Events

Date Code Title Description
FB Suspension of granting procedure